Rituximab monotherapy with eight weekly infusions for relapsed or refractory patients with indolent B cell non-Hodgkin lymphoma mostly pretreated with rituximab: a multicenter phase II study.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples